Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BMP1 | P13497 | 13/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633526 | 0.94 | BACE1 (0.43) | BACE1BMP1MMP2MMP13MEN1 | |
| SCHEMBL5634518 | 0.93 | BACE1 (0.42) | BACE1BMP1MMP2MMP13MEN1 | |
| SCHEMBL5633798 | 0.92 | BACE1 (0.42) | BACE1BMP1MMP2MMP13MEN1 | |
| SCHEMBL7243370 | 0.92 | BACE1 (0.42) | BACE1BMP1MMP2MMP13MEN1 | |
| SCHEMBL6261536 | 0.91 | BMP1 (0.45) | BACE1BMP1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5632828 | 0.88 | BMP1 (0.43) | BACE1BMP1MMP2MMP13SMN1; SMN2 | |
| SCHEMBL6260340 | 0.87 | BMP1 (0.48) | BACE1BMP1MMP13SMN1; SMN2 | |
| SCHEMBL6260176 | 0.86 | BMP1 (0.39) | BACE1BMP1MMP2MMP13SMN1; SMN2 | |
| SCHEMBL5173543 | 0.86 | BACE1 (0.43) | BACE1BMP1MMP2MMP13KEAP1 | |
| SCHEMBL14367267 | 0.82 | SPPL2A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | claimed |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2006-09-07 | — | — | US | claimed |
| EP-1586558-A2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhinitors | G.D. Searle LLC. (US) | 2005-10-19 | — | — | EP | claimed |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2004-04-01 | — | — | US | claimed |
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2003-01-16 | — | — | US | claimed |
| WO-1996022287-A1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013751-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | BACE1 54/4885BMP1 2539/4885MMP2 271/4885 |
| US-20060199822-A1 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | PRSS1, DNPEP, PREP | BACE1 63/4885BMP1 3507/4885MMP2 233/4885 |
| US-20040063771-A1 | Bis-sulfonamide hydroxyethyl-amino retroviral protease inhibitors | DNPEP, PRSS1, PREP | BACE1 54/4885BMP1 2539/4885MMP2 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.